Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All fluvoxamine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFluvoxamineFluvoxamine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Efficacy of Combination Therapy of Fluvoxamine and Favipiravir versus Favipiravir Monotherapy to Prevent Severe COVID-19 among Mild to Moderate COVID-19 Patients: Open-label Randomized Controlled Trial (EFFaCo Study)

Siripongboonsitti et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2023.06.018, EFFaCo, TCTR20210615002
Jun 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
0 0.5 1 1.5 2+ Oxygen therapy -2% Improvement Relative Risk Hospitalization -22% Fluvoxamine  EFFaCo  EARLY TREATMENT  RCT Is early treatment with fluvoxamine beneficial for COVID-19? RCT 327 patients in Thailand (June 2021 - February 2022) Trial underpowered to detect differences c19early.org Siripongboonsitti et al., Int. J. Infe.., Jun 2023 Favors fluvoxamine Favors control
26th treatment shown to reduce risk in November 2021
 
*, now known with p = 0.00014 from 21 studies, recognized in 3 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,200+ studies for 70+ treatments. c19early.org
RCT 327 outpatients in Thailand, showing no significant difference with 50mg fluvoxamine bid added to favipiravir. Authors note that trials showing benefit mostly used 100mg bid.
risk of oxygen therapy, 1.9% higher, RR 1.02, p = 1.00, treatment 4 of 162 (2.5%), control 4 of 165 (2.4%).
risk of hospitalization, 22.2% higher, RR 1.22, p = 0.77, treatment 6 of 162 (3.7%), control 5 of 165 (3.0%), day 28.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Siripongboonsitti et al., 29 Jun 2023, Randomized Controlled Trial, Thailand, peer-reviewed, 9 authors, study period 26 June, 2021 - 22 February, 2022, trial TCTR20210615002 (EFFaCo).
This PaperFluvoxamineAll
Efficacy of Combination Therapy of Fluvoxamine and Favipiravir versus Favipiravir Monotherapy to Prevent Severe COVID-19 among Mild to Moderate COVID-19 Patients: Open-label Randomized Controlled Trial (EFFaCo Study)
M.D. M.Sc Taweegrit Siripongboonsitti, Mullika Buttakosa B.Sc Gaidganok Sornsamdang, M.D Teerapat Ungtrakul, M.D Kriangkrai Tawinprai, B.Sc Tararin Nimmol, B.Sc Mullika Buttakosa, MD Tanadul Jarrusrojwuttikul, M.D Phumin Silapant, M.D Nithi Mahanonda
doi:10.1016/j.ijid.2023.06.018
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References
Bast, Tang, Dahn, Palacio, Increased risk of hospitalisation and death with the delta variant in the USA, Lancet Infect Dis, doi:10.1016/s1473-3099
Bernal, Da Silva, Musungaie, Kovalchuk, None
Bramante, Huling, Tignanelli, Buse, Liebovitz et al., Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19, N Engl J Med, doi:10.1056/NEJMoa2201662
Cai, Yang, Liu, Chen, Shu et al., Experimental treatment with favipiravir for COVID-19: an open-label control study, Engineering, doi:10.1016/j.eng.2020.03.007
Chen, Huang, Cheng, Wu, Chen et al., Favipiravir versus arbidol for COVID-19: a randomized clinical trial, MedRxiv, doi:10.1101/2020.03.17
Chuah, Chow, Hor, Cheng, Ker et al., Efficacy of Early Treatment With Favipiravir on Disease Progression Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19): A Randomized, Open-Label Clinical Trial, Clin Infect Dis, doi:10.1093/cid/ciab962
Du, Chen, Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection, Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.1844
Fung, Liu, The ER stress sensor IRE1 and MAP kinase ERK modulate autophagy induction in cells infected with coronavirus infectious bronchitis virus, Virology, doi:10.1016/j.virol.2019.05.002
Furuta, Komeno, Nakamura, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, doi:10.2183/pjab.93.027
Guo, Harari, Chernecki, Thorlund, Forrest, Fluvoxamine for the Early Treatment of COVID-19: A Meta-analysis of Randomized Clinical Trials, Am J Trop Med Hyg, doi:10.4269/ajtmh.21-1310
Hammond, Leister-Tebbe, Gardner, Abreu, Wisemandle, Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2118542
Hassanipour, Arab-Zozani, Amani, Heidarzad, Fathalipour et al., The efficacy and safety of Favipiravir in treatment of COVID-19: A systematic review and meta-analysis of clinical trials, Scientific reports, doi:10.1038/s41598-021-90551-6
Hoertel, Sánchez-Rico, De La Muela, Abellán, Blanco et al., Risk of Death in Individuals Hospitalized for COVID-19 With and Without Psychiatric Disorders: An Observational Multicenter Study in France, Biol Psychiatry Glob Open Sci, doi:10.1016/j.bpsgos.2021.12.007
Homolak, Kodvanj, Widely available lysosome targeting agents should be considered as potential therapy for COVID-19, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.106044
Ivashchenko, Dmitriev, Vostokova, Azarova, Blinow et al., AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial, Clinical Infectious Diseases, doi:10.1093/cid/ciaa1176
Lee, Vigod, Bortolussi-Courval, Hanula, Boulware et al., Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-analysis, JAMA Netw Open, doi:10.1001/jamanetworkopen.2022.6269
Lenze, Mattar, Zorumski, Stevens, Schweiger et al., Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial, Jama, doi:10.1001/jama.2020.22760
Mccarthy, Naggie, Boulware, Lindsell, Stewart et al., Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial, doi:10.1101/2022.10.17.22281178
Németh, Szûcs, Vitrai, Juhász, Németh et al., Fluoxetine use is associated with improved survival of patients with COVID-19 pneumonia: A retrospective casecontrol study, Ideggyogy Sz, doi:10.18071/isz.74.0389
Oskotsky, Maric, Tang, Oskotsky, Wong et al., Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants, JAMA Netw Open, doi:10.1001/jamanetworkopen.2021.33090
Reis, Santos Moreira-Silva, Silva, Thabane, Milagres et al., Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial, Lancet Glob Health, doi:10.1016/s2214-109x(21)00448-4
Reis, Santos, Silva, Silva, Thabane et al., Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset COVID-19 : A Randomized Platform Trial, Ann Intern Med, doi:10.7326/m22-3305
Reyes, Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients, N Engl J Med, doi:10.1056/NEJMoa2116044
Schlienger, Meier, Effect of selective serotonin reuptake inhibitors on platelet activation: can they prevent acute myocardial infarction?, Am J Cardiovasc Drugs, doi:10.2165/00129784-200303030-00001
Seftel, Boulware, Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19, Open Forum Infect Dis, doi:10.1093/ofid/ofab050
Seo, Kim, Bae, Park, Chung et al., Fluvoxamine Treatment of Patients with Symptomatic COVID-19 in a Community Treatment Center: A Preliminary Result of Randomized Controlled Trial, Infect Chemother, doi:10.3947/ic.2021.0142
Shrestha, Budhathoki, Khadka, Shah, Pokharel et al., Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis, Virology journal, doi:10.1186/s12985-020-01412-z
Sukhatme, Reiersen, Vayttaden, Sukhatme, Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19, Front Pharmacol, doi:10.3389/fphar.2021.652688
{ 'indexed': {'date-parts': [[2024, 3, 26]], 'date-time': '2024-03-26T21:51:53Z', 'timestamp': 1711489913784}, 'reference-count': 29, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2023, 9, 1]], 'date-time': '2023-09-01T00:00:00Z', 'timestamp': 1693526400000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2023, 6, 20]], 'date-time': '2023-06-20T00:00:00Z', 'timestamp': 1687219200000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}], 'funder': [ { 'DOI': '10.13039/100016175', 'name': 'Chulabhorn Royal Academy', 'doi-asserted-by': 'publisher'}], 'content-domain': { 'domain': [ 'clinicalkey.fr', 'clinicalkey.jp', 'clinicalkey.es', 'clinicalkey.com.au', 'clinicalkey.com', 'ijidonline.com', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2023, 9]]}, 'DOI': '10.1016/j.ijid.2023.06.018', 'type': 'journal-article', 'created': {'date-parts': [[2023, 6, 30]], 'date-time': '2023-06-30T06:07:12Z', 'timestamp': 1688105232000}, 'page': '211-219', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 5, 'title': 'Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir monotherapy to ' 'prevent severe COVID-19 among mild to moderate COVID-19 patients: Open-label randomized ' 'controlled trial (EFFaCo study)', 'prefix': '10.1016', 'volume': '134', 'author': [ { 'ORCID': 'http://orcid.org/0000-0001-7256-9982', 'authenticated-orcid': False, 'given': 'Taweegrit', 'family': 'Siripongboonsitti', 'sequence': 'first', 'affiliation': []}, {'given': 'Teerapat', 'family': 'Ungtrakul', 'sequence': 'additional', 'affiliation': []}, {'given': 'Kriangkrai', 'family': 'Tawinprai', 'sequence': 'additional', 'affiliation': []}, {'given': 'Tararin', 'family': 'Nimmol', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mullika', 'family': 'Buttakosa', 'sequence': 'additional', 'affiliation': []}, {'given': 'Gaidganok', 'family': 'Sornsamdang', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Tanadul', 'family': 'Jarrusrojwuttikul', 'sequence': 'additional', 'affiliation': []}, {'given': 'Phumin', 'family': 'Silapant', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nithi', 'family': 'Mahanonda', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.ijid.2023.06.018_bib0001', 'doi-asserted-by': 'crossref', 'first-page': '1397', 'DOI': '10.1056/NEJMoa2118542', 'article-title': 'Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19', 'volume': '386', 'author': 'Hammond', 'year': '2022', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0002', 'doi-asserted-by': 'crossref', 'first-page': '509', 'DOI': '10.1056/NEJMoa2116044', 'article-title': 'Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients', 'volume': '386', 'author': 'Jayk Bernal', 'year': '2022', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0003', 'unstructured': 'United States Food and Drug Administration, FDA Network of European ' 'World Shops. RELEASE, coronavirus (COVID-19) update: FDA authorizes ' 'first oral antiviral for treatment of COVID-19, ' 'https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19; ' '2021 [accessed 22 December 2021].'}, { 'key': '10.1016/j.ijid.2023.06.018_sbref0004', 'series-title': 'Clinical practice guideline to diagnosis, treatment and prevention ' 'COVID-19 for Physicain and health care provider', 'year': '2021'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0005', 'doi-asserted-by': 'crossref', 'first-page': '11022', 'DOI': '10.1038/s41598-021-90551-6', 'article-title': 'Martinez-de-Hoyo R. The efficacy and safety of favipiravir in treatment ' 'of COVID-19: a systematic review and meta-analysis of clinical trials', 'volume': '11', 'author': 'Hassanipour', 'year': '2021', 'journal-title': 'Sci Rep'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0006', 'doi-asserted-by': 'crossref', 'first-page': '141', 'DOI': '10.1186/s12985-020-01412-z', 'article-title': 'Favipiravir versus other antiviral or standard of care for COVID-19 ' 'treatment: a rapid systematic review and meta-analysis', 'volume': '17', 'author': 'Shrestha', 'year': '2020', 'journal-title': 'Virol J'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0007', 'doi-asserted-by': 'crossref', 'first-page': 'e432', 'DOI': '10.1093/cid/ciab962', 'article-title': 'Efficacy of early treatment with favipiravir on disease progression ' 'among high-risk patients with coronavirus disease 2019 (COVID-19): a ' 'randomized, open-label clinical trial', 'volume': '75', 'author': 'Chuah', 'year': '2022', 'journal-title': 'Clin Infect Dis'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0008', 'doi-asserted-by': 'crossref', 'first-page': '242', 'DOI': '10.1002/cpt.1844', 'article-title': 'Favipiravir: pharmacokinetics and concerns about clinical trials for ' '2019-nCoV infection', 'volume': '108', 'author': 'Du', 'year': '2020', 'journal-title': 'Clin Pharmacol Ther'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0009', 'doi-asserted-by': 'crossref', 'first-page': '449', 'DOI': '10.2183/pjab.93.027', 'article-title': 'Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase', 'volume': '93', 'author': 'Furuta', 'year': '2017', 'journal-title': 'Proc Jpn Acad Ser B Phys Biol Sci'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0010', 'first-page': '1192', 'article-title': 'Experimental treatment with favipiravir for COVID-19: an open-label ' 'control study', 'volume': '6', 'author': 'Cai', 'year': '2020', 'journal-title': 'Engineering (Beijing)'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0011', 'article-title': 'Favipiravir versus arbidol for clinical recovery rate in moderate and ' 'severe adult COVID-19 patients: a prospective, multicenter, open-label, ' 'randomized clinical trial', 'volume': '12', 'author': 'Chen', 'year': '2021', 'journal-title': 'Front Pharmacol'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0012', 'doi-asserted-by': 'crossref', 'first-page': '531', 'DOI': '10.1093/cid/ciaa1176', 'article-title': 'AVIFAVIR for treatment of patients with moderate coronavirus disease ' '2019 (COVID-19): interim results of a Phase II/III multicenter ' 'randomized clinical trial', 'volume': '73', 'author': 'Ivashchenko', 'year': '2021', 'journal-title': 'Clin Infect Dis'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0013', 'doi-asserted-by': 'crossref', 'DOI': '10.3389/fphar.2021.652688', 'article-title': 'Fluvoxamine: a review of its mechanism of action and its role in ' 'COVID-19', 'volume': '12', 'author': 'Sukhatme', 'year': '2021', 'journal-title': 'Front Pharmacol'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0014', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.ijantimicag.2020.106044', 'article-title': 'Widely available lysosome targeting agents should be considered as ' 'potential therapy for COVID-19', 'volume': '56', 'author': 'Homolak', 'year': '2020', 'journal-title': 'Int J Antimicrob Agents'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0015', 'doi-asserted-by': 'crossref', 'first-page': '34', 'DOI': '10.1016/j.virol.2019.05.002', 'article-title': 'The ER stress sensor IRE1 and MAP kinase ERK modulate autophagy ' 'induction in cells infected with coronavirus infectious bronchitis ' 'virus', 'volume': '533', 'author': 'Fung', 'year': '2019', 'journal-title': 'Virology'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0016', 'doi-asserted-by': 'crossref', 'first-page': '149', 'DOI': '10.2165/00129784-200303030-00001', 'article-title': 'Effect of selective serotonin reuptake inhibitors on platelet ' 'activation: can they prevent acute myocardial infarction?', 'volume': '3', 'author': 'Schlienger', 'year': '2003', 'journal-title': 'Am J Cardiovasc Drugs'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0017', 'doi-asserted-by': 'crossref', 'first-page': '2292', 'DOI': '10.1001/jama.2020.22760', 'article-title': 'Fluvoxamine vs placebo and clinical deterioration in outpatients with ' 'symptomatic COVID-19: a randomized clinical trial', 'volume': '324', 'author': 'Lenze', 'year': '2020', 'journal-title': 'JAMA'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0018', 'doi-asserted-by': 'crossref', 'first-page': '1315', 'DOI': '10.4269/ajtmh.21-1310', 'article-title': 'Fluvoxamine for the early treatment of COVID-19: a meta-analysis of ' 'randomized clinical trials', 'volume': '106', 'author': 'Guo', 'year': '2022', 'journal-title': 'Am J Trop Med Hyg'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0019', 'doi-asserted-by': 'crossref', 'first-page': 'e42', 'DOI': '10.1016/S2214-109X(21)00448-4', 'article-title': 'Effect of early treatment with fluvoxamine on risk of emergency care ' 'and hospitalisation among patients with COVID-19: the TOGETHER ' 'randomised, platform clinical trial', 'volume': '10', 'author': 'Reis', 'year': '2022', 'journal-title': 'Lancet Glob Health'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0020', 'doi-asserted-by': 'crossref', 'first-page': '667', 'DOI': '10.7326/M22-3305', 'article-title': 'Oral fluvoxamine with inhaled budesonide for treatment of early-onset ' 'COVID-19: a randomized platform trial', 'volume': '176', 'author': 'Reis', 'year': '2023', 'journal-title': 'Ann Intern Med'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0021', 'doi-asserted-by': 'crossref', 'first-page': 'ofab050', 'DOI': '10.1093/ofid/ofab050', 'article-title': 'Prospective cohort of fluvoxamine for early treatment of coronavirus ' 'Disease 19', 'volume': '8', 'author': 'Seftel', 'year': '2021', 'journal-title': 'Open Forum Infect Dis'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0022', 'doi-asserted-by': 'crossref', 'unstructured': 'McCarthy MW, Naggie S, Boulware DR, Lindsell CJ, Stewart TG, Felker GM, ' 'et\xa0al. Fluvoxamine for outpatient treatment of COVID-19: a ' 'decentralized, placebo-controlled, randomized, platform clinical trial. ' 'medRxiv. 01 November 2022. ' 'https://www.medrxiv.org/content/10.1101/2022.10.17.22281178 [accessed 2 ' 'November 2022].', 'DOI': '10.1093/ofid/ofac492.1881'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0023', 'doi-asserted-by': 'crossref', 'first-page': '599', 'DOI': '10.1056/NEJMoa2201662', 'article-title': 'Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19', 'volume': '387', 'author': 'Bramante', 'year': '2022', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0024', 'doi-asserted-by': 'crossref', 'first-page': '389', 'DOI': '10.18071/isz.74.0389', 'article-title': 'Fluoxetine use is associated with improved survival of patients with ' 'COVID-19 pneumonia: a retrospective case-control study', 'volume': '74', 'author': 'Németh', 'year': '2021', 'journal-title': 'Ideggyogy Sz'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0025', 'doi-asserted-by': 'crossref', 'first-page': '56', 'DOI': '10.1016/j.bpsgos.2021.12.007', 'article-title': 'Risk of death in individuals hospitalized for COVID-19 with and without ' 'psychiatric disorders: an observational multicenter study in France', 'volume': '3', 'author': 'Hoertel', 'year': '2023', 'journal-title': 'Biol Psychiatry Glob Open Sci'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0026', 'doi-asserted-by': 'crossref', 'DOI': '10.1001/jamanetworkopen.2021.33090', 'article-title': 'Mortality risk among patients with COVID-19 prescribed selective ' 'serotonin reuptake inhibitor antidepressants', 'volume': '4', 'author': 'Oskotsky', 'year': '2021', 'journal-title': 'JAMA Netw Open'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0027', 'doi-asserted-by': 'crossref', 'DOI': '10.1001/jamanetworkopen.2022.6269', 'article-title': 'Fluvoxamine for outpatient management of COVID-19 to prevent ' 'hospitalization: a systematic review and meta-analysis', 'volume': '5', 'author': 'Lee', 'year': '2022', 'journal-title': 'JAMA Netw Open'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0028', 'doi-asserted-by': 'crossref', 'first-page': '102', 'DOI': '10.3947/ic.2021.0142', 'article-title': 'Fluvoxamine treatment of patients with symptomatic COVID-19 in a ' 'community treatment center: a preliminary result of randomized ' 'controlled trial', 'volume': '54', 'author': 'Seo', 'year': '2022', 'journal-title': 'Infect Chemother'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0029', 'doi-asserted-by': 'crossref', 'first-page': '1629', 'DOI': '10.1016/S1473-3099(21)00685-X', 'article-title': 'Increased risk of hospitalisation and death with the delta variant in ' 'the USA', 'volume': '21', 'author': 'Bast', 'year': '2021', 'journal-title': 'Lancet Infect Dis'}], 'container-title': 'International Journal of Infectious Diseases', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S1201971223006410?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S1201971223006410?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2023, 10, 13]], 'date-time': '2023-10-13T19:14:19Z', 'timestamp': 1697224459000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S1201971223006410'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 9]]}, 'references-count': 29, 'alternative-id': ['S1201971223006410'], 'URL': 'http://dx.doi.org/10.1016/j.ijid.2023.06.018', 'relation': {}, 'ISSN': ['1201-9712'], 'subject': ['Infectious Diseases', 'Microbiology (medical)', 'General Medicine'], 'container-title-short': 'International Journal of Infectious Diseases', 'published': {'date-parts': [[2023, 9]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir ' 'monotherapy to prevent severe COVID-19 among mild to moderate COVID-19 ' 'patients: Open-label randomized controlled trial (EFFaCo study)', 'name': 'articletitle', 'label': 'Article Title'}, { 'value': 'International Journal of Infectious Diseases', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.ijid.2023.06.018', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2023 The Author(s). Published by Elsevier Ltd on behalf of International ' 'Society for Infectious Diseases.', 'name': 'copyright', 'label': 'Copyright'}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit